REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlant Health Regulatory News (PHC)

Share Price Information for Plant Health (PHC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4.41
Bid: 4.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.70 (17.50%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 4.41
PHC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Re Agreement

8 Apr 2015 07:00

RNS Number : 5287J
Plant Health Care PLC
08 April 2015
 

8 April 2015

 

 

PLANT HEALTH CARE plc

 

("Plant Health Care" or the "Company")

 

Plant Health Care Signs First Innatus™ 3G Evaluation Agreement With Major Industry Player

 

Company Continues To ExpandR&D Resources 

 

Plant Health Care (AIM: PHC), a leading provider of novel patent-protected biological products to the global agriculture markets, is pleased to announce that it has signed an agreement with a major industry player in the agricultural space regarding the evaluation of its Innatus™ 3G peptide platform. This technology platform enables the design, production and screening of a large pipeline of peptides with diverse biostimulant properties. The peptides can be used for both seed treatment and foliar applications. They can also be combined with conventional crop protection chemicals, making them highly complementary to existing production practices.

 

 

Paul Schmidt, CEO of Plant Health Care, stated, "Over the past few months, we have been in active discussions with a number of major industry players that have the development and commercialization capabilities to exploit the full potential of our Innatus3G peptide platform. The response has been very positive and we are pleased to announce our first agreement arising from these discussions as we continue the dialogue with other major players."

 

While developing opportunities for its Innatus™ 3G peptide platform, Plant Health Care has continued to expand its research and development effort under the leadership of its Chief Scientific Officer, Dr. Zhongmin Wei. Over the past 18 months, the company added 4 research staff and, in 2015, plans to double its current researchpersonnel. In addition, by mid-year, the company will relocate to a larger research facility in Seattle with over three times the square footage of its existing lab. The expanded workspace, staff increase, and planned addition of new growth chambers are expected to significantly accelerate the company's ability to develop new peptide families.

 

- ENDS -

For further information, please contact:

Plant Health Care plc

Paul Schmidt, Chief Executive Officer Tel: +1 (919) 926 1600

 

Liberum Capital - Nomad and Broker

Clayton Bush Tel: +44 (0) 20 3100 2000

 

LHA

Ed McGregor / Jody Burfening Tel: +1 (212) 838 3777

 

Company website: www.planthealthcare.com

 

About Plant Health Care: Plant Health Care is a leading provider of novel patent-protected biological products to the global agriculture markets. Through the commercialisation of these products, Plant Health Care is capitalising on current long-term trends toward natural systems and biological products for plant care and soil and water management. The Company's ordinary shares have been quoted on the AIM market of the London Stock Exchange since July 2004 (ticker symbol: PHC).

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGREALLXEDXSEFF
Date   Source Headline
8th May 20247:00 amRNSTrading Update
22nd Apr 20247:00 amRNSApproval of Harpinαβ in Belgium
16th Apr 20247:00 amRNSPlant Health Care--China Distribution with AMVAC
4th Apr 20247:00 amRNSApproval of PHC68949 in Mexico
4th Mar 20241:55 pmRNSHolding(s) in Company
24th Jan 20244:27 pmRNSHolding(s) in Company
2nd Jan 20247:00 amRNSBrazil approves TEIKKOâ„¢
20th Dec 20237:00 amRNSBoard Changes and Grant of Options
19th Dec 20233:34 pmRNSHolding(s) in Company
30th Nov 20231:45 pmRNSHolding(s) in Company
28th Nov 20233:16 pmRNSHolding(s) in Company
27th Nov 20234:03 pmRNSHolding(s) in Company
27th Nov 20231:27 pmRNSHolding(s) in Company
24th Nov 20234:19 pmRNSDirector/PDMR Shareholding
24th Nov 202310:57 amRNSDirector/PDMR Shareholding
23rd Nov 20232:31 pmRNSHolding(s) in Company
22nd Nov 20237:00 amRNSTrading Update
31st Oct 20237:00 amRNSChange of Adviser
20th Oct 20237:00 amRNSHolding(s) in Company
3rd Oct 20236:28 pmRNSPlant Health Care PREtec Product with Agrii UK
28th Sep 20237:00 amRNSNew PREtec Products Announced
27th Sep 20237:00 amRNSUnaudited Interim Results
25th Sep 20237:00 amRNSPREtec Products Submitted for Regulatory Approval
31st Aug 20237:00 amRNSNotice of Results & Investor Presentation
18th Aug 20237:00 amRNSNew Product Regulatory Approval In Brazil
1st Aug 20237:00 amRNSApproval for Sale of Harpin aß Granted in Poland
24th Jul 20237:00 amRNSGrant of Options
12th Jul 202312:27 pmRNSHolding(s) in Company
30th Jun 20235:07 pmRNSNotification of Major Holdings
28th Jun 202312:29 pmRNSHolding(s) in Company
27th Jun 20234:08 pmRNSHolding(s) in Company
27th Jun 20231:08 pmRNSDirector Shareholding
23rd Jun 20237:00 amRNSResult of Fundraising
22nd Jun 20234:35 pmRNSFundraising to raise up to US$3.6 million
14th Jun 20237:00 amRNSWilbur Ellis Agreement
13th Jun 20231:43 pmRNSResult of AGM
30th May 20237:00 amRNSHolding(s) in Company
24th May 20231:12 pmRNSHolding(s) in Company
19th May 20235:55 pmRNSPublication of Annual Report and Notice of AGM
18th May 20237:00 amRNSResult of Consultation
9th May 20237:00 amRNSPHC68949 granted first stage of approval in Brazil
2nd May 20237:10 amRNSResults for the year ended 31 December 2022
12th Apr 20232:33 pmRNSNotice of Results
5th Apr 20235:29 pmRNSHolding(s) in Company
8th Mar 20232:45 pmRNSExercise of Options
2nd Mar 20237:00 amRNSBiofungicide PHC279 Approved by US EPA
1st Mar 20237:00 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSTrading Statement
30th Jan 202312:08 pmRNSSignificant Shareholder
18th Jan 20237:00 amRNSBoard Appointments

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.